|
Market Closed -
Nasdaq
00:00:00 07/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 222.89 USD | -0.31% |
|
-2.54% | +26.65% |
| 10-02 | Biogen's experimental lupus drug shows benefit against skin symptoms | RE |
| 10-02 | Biogen Says Litifilimab Shows Efficacy in New 52-Week Phase 2 Data | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- BIIB Stock
- Consensus Biogen Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
